-
Medical journals
- Career
Diabetes and obesity - Issue 44/2022
Editorial
Reviews
7491New therapeutic indications for SGLT2 inhibitorsZbynek Schroner
95Effect of intensive lifestyle modification in patients with obesity (even extreme obesity) on cardiometabolic parametersAdela Penesová, Jana Babjaková, Viktor Bielik, Žofia Rádiková, Libuša Kubáňová
Case studies
103Practical experience with empagliflozin in the light of new possibilities: case reportsIveta Marková, Lenka Godál, Eva Horská, Zbynek Schroner
Clinical studies
109MAFLD screening in real practice in Slovakia: the SIRIUS studyMária Szántová, Tomáš Koller, Marek Rác, Svetlana Adamcová-Selčanová, Xénia Faktorová, Martina Jakabovičová, Zuzana Urkovičová, Viliam Mojto, Peter Jarčuška, Martin Janíčko, Ubomír Skladaný
News
129
News
133Jarná diabetologická konferencia: správa z odborného podujatiaJozef Polko, Zbynek Schroner
138Zpráva z kongresu Americké diabetologické asociace 2022Martin Haluzík
142Sumár z 58. výročného kongresu Európskej asociácie pre štúdium diabetuPeter Novodvorský
Diabetes and obesity
2022 Issue 44
Most read in this issue- MAFLD screening in real practice in Slovakia: the SIRIUS study
- New therapeutic indications for SGLT2 inhibitors
- Finerenone – a new option to reduce the risk of progression of renal and cardiovascular damage in patients with chronic kidney disease and type 2 diabetes mellitus
- Effect of intensive lifestyle modification in patients with obesity (even extreme obesity) on cardiometabolic parameters
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career